ライフサイエンスコーパス: gastroesophageal reflux disease

1 to evaluate for the presence of concomitant gastroesophageal reflux disease.

2 thereby conclusively distinguishing it from gastroesophageal reflux disease.

3 fundoplication is an effective treatment for gastroesophageal reflux disease.

4 increasingly recognized disease that mimics gastroesophageal reflux disease.

5 ders, including irritable bowel syndrome and gastroesophageal reflux disease.

6 ct patients from developing complications of gastroesophageal reflux disease.

7 itis is a new disease commonly confused with gastroesophageal reflux disease.

8 esophageal motor disorders and treatment of gastroesophageal reflux disease.

9 the association between BMI and symptoms of gastroesophageal reflux disease.

10 relation to the occurrence and management of gastroesophageal reflux disease.

11 and obese persons are at increased risk for gastroesophageal reflux disease.

12 actors usually indicative of severe types of gastroesophageal reflux disease.

13 d-mediated event and a reliable indicator of gastroesophageal reflux disease.

14 directions in the research and treatment of gastroesophageal reflux disease.

15 eading to duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease.

16 ithout Barrett's esophagus or other types of gastroesophageal reflux disease.

17 ux surgery is performed for the treatment of gastroesophageal reflux disease.

18 esophagus in patients with mild-to-moderate gastroesophageal reflux disease.

19 ortened esophagus and stricture secondary to gastroesophageal reflux disease.

20 ormal-appearing cardia are manifestations of gastroesophageal reflux disease.

21 agus and adenocarcinoma are complications of gastroesophageal reflux disease.

22 astroesophageal junction and its relation to gastroesophageal reflux disease.

23 hageal junction are histologic indicators of gastroesophageal reflux disease.

24 that can occur in a subset of patients with gastroesophageal reflux disease.

25 c approach to the treatment of patients with gastroesophageal reflux disease.

26 ery effective and long-lasting treatment for gastroesophageal reflux disease.

27 Obesity is associated with a risk of gastroesophageal reflux disease.

28 llow-up after ARS in pediatric patients with gastroesophageal reflux disease.

29 180-degree LAF for the surgical treatment of gastroesophageal reflux disease.

30 st frequently performed surgical therapy for gastroesophageal reflux disease.

31 ved cells is a novel potential treatment for gastroesophageal reflux disease.

32 drome (IBS) frequently overlap with those of gastroesophageal reflux disease.

33 gents widely prescribed for the treatment of gastroesophageal reflux disease.

34 ng bowel habit (15%), constipation (13%) and gastroesophageal reflux disease (12%).

35 lipidemia (24.5%), hypertension (21.9%), and gastroesophageal reflux disease (17.3%).

36 The presence of gastroesophageal reflux disease (26%), esophageal strict

37 ere rhinitis (84.0%), sinusitis (47.8%), and gastroesophageal reflux disease (46.3%).

38 structive sleep apnea may be associated with gastroesophageal reflux disease, a strong risk factor fo

39 allergic rhinitis, chronic rhinitis, asthma, gastroesophageal reflux disease, adenotonsillitis, sleep

40 Risk factors evaluated included gastroesophageal reflux disease, alcohol consumption, sm

41 uency, severity, and duration of symptoms of gastroesophageal reflux disease among randomly selected

42 er improvement in quality of life related to gastroesophageal reflux disease and a 50% or greater red

43 rs to result in decreased prevalence of both gastroesophageal reflux disease and adenocarcinoma of th

44 and surgical techniques in the management of gastroesophageal reflux disease and constipation also ma

45 patterns from biopsies of patients with EoE, gastroesophageal reflux disease and controls.

46 11,945 patients aged 18 years and older with gastroesophageal reflux disease and erosive esophagitis.

47 oplication was performed in 758 patients for gastroesophageal reflux disease and in 99 for paraesopha

48 allenges to diagnosis, including the role of gastroesophageal reflux disease and proton pump inhibito

49 75-year-old woman with a medical history of gastroesophageal reflux disease and type II diabetes pre

50 g the role of nonacid reflux in cough due to gastroesophageal reflux disease, and 3) developing relia

51 cent had symptoms of dyspnea, 87 percent had gastroesophageal reflux disease, and 54 percent had nasa

52 lization for asthma, mechanical ventilation, gastroesophageal reflux disease, and aspiration or other

53 lation), and prior diagnoses (eg, pneumonia, gastroesophageal reflux disease, and other comorbidities

54 the individual to irritable bowel syndrome, gastroesophageal reflux disease, and peptic ulcer diseas

55 Laparoscopic procedures for gastroesophageal reflux disease appear to be as effectiv

56 e mechanisms involved in the pathogenesis of gastroesophageal reflux disease are complex and multifac

57 The high reoperation rate and incidence of gastroesophageal reflux disease are concerning.

58 ractical concepts regarding the treatment of gastroesophageal reflux disease are developed, based on

59 Typical symptoms of gastroesophageal reflux disease are heartburn and regurg

60 pump inhibitors and has focused attention on gastroesophageal reflux disease as a causative factor in

61 treat a variety of gastric disorders such as gastroesophageal reflux disease, autoimmune gastritis, g

62 factors for EAC have been identified-mainly gastroesophageal reflux disease, Barrett's esophagus, ob

63 We prospectively assessed 100 patients with gastroesophageal reflux disease before and after sphinct

64 shown to be a safe and effective therapy for gastroesophageal reflux disease, but its effect on the L

65 Symptoms frequently mimic those of gastroesophageal reflux disease, but the diseases are di

66 iteria consisted of a confirmed diagnosis of gastroesophageal reflux disease by an abnormal esophagea

67 , screening 50-year-old men with symptoms of gastroesophageal reflux disease by Cytosponge is cost ef

68 emerging disease that is distinguished from gastroesophageal reflux disease by the expression of a u

69 ished before their place in the treatment of gastroesophageal reflux disease can be determined.

70 suppression, have been confirmed in EoE and gastroesophageal reflux disease cell cultures.

71 Risk factors include gastroesophageal reflux disease, central obesity, and sm

72 Gastroesophageal reflux disease complicated by Barrett e

73 Gastroesophageal reflux disease complicated by Barrett's

74 search into the use of these technologies in gastroesophageal reflux disease continues to accelerate,

75 95% confidence interval [CI]: 1.04-2.67) or gastroesophageal reflux disease controls (OR = 1.61; 95%

76 bjects with gastroesophageal reflux disease (gastroesophageal reflux disease controls, n = 1332), and

77 sing and treating chest pain associated with gastroesophageal reflux disease, correlates abnormal amb

78 terms: heartburn, regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, lary

79 lowing: heartburn, regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, lary

80 esophageal mucosal injury, the diagnosis of gastroesophageal reflux disease currently rests on 24-ho

81 Early aggressive surgical treatment of gastroesophageal reflux disease decreases the rate of br

82 Mild-to-moderate chronic tissue injury in gastroesophageal reflux disease differentially affects m

83 es for detailed drugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive

84 ugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, a

85 of diseases such as functional dyspepsia and gastroesophageal reflux disease (e.g. vomiting, disorder

86 ecome available in the last 2 years for many gastroesophageal reflux disease endotherapies, providing

87 l gastrointestinal complications of obesity: gastroesophageal reflux disease, erosive esophagitis, Ba

88 Most patients with gastroesophageal reflux disease experience symptomatic r

89 This issue provides a clinical overview of gastroesophageal reflux disease, focusing on diagnosis,

90 gus (n = 1059) with those from subjects with gastroesophageal reflux disease (gastroesophageal reflux

91 .1; 95% confidence interval [CI], 2.9-12.9), gastroesophageal reflux disease (GERD) (RR, 1.9; 95% CI,

92 lin, leptin, and ghrelin are associated with gastroesophageal reflux disease (GERD) and Barrett's eso

93 We examined the incidence and predictors of gastroesophageal reflux disease (GERD) and dyspepsia and

94 The potential association between gastroesophageal reflux disease (GERD) and extraesophage

95 Skinner to the understanding of gastroesophageal reflux disease (GERD) and its complicat

96 might represent an alternative treatment of gastroesophageal reflux disease (GERD) and may provide d

97 has enormous potential for the treatment of gastroesophageal reflux disease (GERD) and other esophag

98 The advent of the Montreal definition of gastroesophageal reflux disease (GERD) and the Rome III

99 agement of extraesophageal manifestations of gastroesophageal reflux disease (GERD) and to compare th

100 Whether inflammation of the cardia indicates gastroesophageal reflux disease (GERD) and/or is a manif

101 Lung transplant recipients with documented gastroesophageal reflux disease (GERD) are at increased

102 Current diagnostic tests for gastroesophageal reflux disease (GERD) are suboptimal an

103 hageal eosinophilia who were thought to have gastroesophageal reflux disease (GERD) but who did not r

104 Management of gastroesophageal reflux disease (GERD) commonly starts w

105 t clear why only a minority of patients with gastroesophageal reflux disease (GERD) develop Barrett's

106 .4)] were included; 70% had been treated for gastroesophageal reflux disease (GERD) during infancy.

107 However, gastroesophageal reflux disease (GERD) has remained the

108 The histologic changes associated with acute gastroesophageal reflux disease (GERD) have not been stu

109 The aim was to compare recurrence of gastroesophageal reflux disease (GERD) in children rando

110 RAs) are frequently used in the treatment of gastroesophageal reflux disease (GERD) in children; howe

111 ull-thickness plication for the treatment of gastroesophageal reflux disease (GERD) in comparison wit

112 n (TF) can decrease or eliminate features of gastroesophageal reflux disease (GERD) in some patients

113 Gastroesophageal reflux disease (GERD) is a chronic diso

114 Gastroesophageal reflux disease (GERD) is a common diagn

115 Gastroesophageal reflux disease (GERD) is a common medic

116 Severe gastroesophageal reflux disease (GERD) is a lifelong pro

117 Gastroesophageal reflux disease (GERD) is a risk factor

118 It has been suggested that gastroesophageal reflux disease (GERD) is a risk factor

119 Gastroesophageal reflux disease (GERD) is a very common

120 Gastroesophageal reflux disease (GERD) is associated wit

121 The pathogenesis of gastroesophageal reflux disease (GERD) is complex and in

122 hageal mucosal injury across the spectrum of gastroesophageal reflux disease (GERD) is controversial.

123 As the economic burden of gastroesophageal reflux disease (GERD) is largely weight

124 illustrated by the Montreal classification, gastroesophageal reflux disease (GERD) is much more than

125 Gastroesophageal reflux disease (GERD) is prevalent worl

126 ump inhibitor (PPI) therapy in patients with gastroesophageal reflux disease (GERD) is reported in up

127 Gastroesophageal reflux disease (GERD) is the most commo

128 Gastroesophageal reflux disease (GERD) is the most preva

129 Gastroesophageal reflux disease (GERD) is the strongest

130 f Helicobacter pylori in the pathogenesis of gastroesophageal reflux disease (GERD) is unknown.

131 Exclusion criteria included symptoms of gastroesophageal reflux disease (GERD) more than once a

132 Many individuals with gastroesophageal reflux disease (GERD) never visit their

133 f an underlying acid peptic disorder such as gastroesophageal reflux disease (GERD) nor should it pre

134 is name, currently used for the treatment of gastroesophageal reflux disease (GERD) or completing Hel

135 Most patients with gastroesophageal reflux disease (GERD) report that stres

136 It has been speculated that gastroesophageal reflux disease (GERD) represents a risk

137 has been developed for use in patients with gastroesophageal reflux disease (GERD) symptoms despite

138 discrepancy reflects a higher prevalence of gastroesophageal reflux disease (GERD) symptoms or a hig

139 assessed the utility of NBI in patients with gastroesophageal reflux disease (GERD) symptoms.

140 Patients with gastroesophageal reflux disease (GERD) who are not respo

141 phagus (cases) were matched to subjects with gastroesophageal reflux disease (GERD) without Barrett's

142 tailed critique of objective measurements of gastroesophageal reflux disease (GERD) would improve man

143 BS), 3.0; dyspepsia, 1.8; constipation, 3.9; gastroesophageal reflux disease (GERD), 9.7.

144 Gastroesophageal reflux disease (GERD), a condition comm

145 cluding Crohn disease (CrD), celiac disease, gastroesophageal reflux disease (GERD), and eosinophilic

146 frequency of irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and overactive b

147 e upper airways dysfunction syndrome (RUDS), gastroesophageal reflux disease (GERD), and rare cases o

148 rm use of PPIs for three common indications: gastroesophageal reflux disease (GERD), Barrett's esopha

149 sophagus has been proposed for patients with gastroesophageal reflux disease (GERD), but there is lit

150 eneral U.S. population and for patients with gastroesophageal reflux disease (GERD), diabetes mellitu

151 n several pathophysiological states, such as gastroesophageal reflux disease (GERD), functional dyspe

152 Gastroesophageal reflux disease (GERD), functional dyspe

153 The association of body mass index and gastroesophageal reflux disease (GERD), including its co

154 Barrett esophagus, a complication of gastroesophageal reflux disease (GERD), predisposes pati

155 ients, who had a previous fundoplication for gastroesophageal reflux disease (GERD), underwent reoper

156 Unlike gastroesophageal reflux disease (GERD), whose symptoms c

157 only used in the diagnosis and management of gastroesophageal reflux disease (GERD).

158 ctional gastrointestinal disorders (FGD) and gastroesophageal reflux disease (GERD).

159 e existing endoscopy-based interventions for gastroesophageal reflux disease (GERD).

160 a significant increase in the prevalence of gastroesophageal reflux disease (GERD).

161 in the past year has centered on surgery for gastroesophageal reflux disease (GERD).

162 on atypical/extraesophageal manifestation of gastroesophageal reflux disease (GERD).

163 one combination vs omeprazole monotherapy in gastroesophageal reflux disease (GERD).

164 s and many do not report typical symptoms of gastroesophageal reflux disease (GERD).

165 the relaxed EGJ was altered in patients with gastroesophageal reflux disease (GERD).

166 mptoms (URS) among patients with symptomatic gastroesophageal reflux disease (GERD).

167 ) during gastric distention in patients with gastroesophageal reflux disease (GERD).

168 en fundoplication (CNF) for the treatment of gastroesophageal reflux disease (GERD).

169 enewed interest in the surgical treatment of gastroesophageal reflux disease (GERD).

170 dal anti-inflammatory drugs) and symptoms of gastroesophageal reflux disease (GERD).

171 urgical option for patients with early-stage gastroesophageal reflux disease (GERD).

172 procedure of choice for obese patients with gastroesophageal reflux disease (GERD).

173 y risk factors for both BE and EA is chronic gastroesophageal reflux disease (GERD).

174 responders and treatment-naive patients with gastroesophageal reflux disease (GERD).

175 n accurate method for diagnosing adults with gastroesophageal reflux disease (GERD).

176 s for a range of medical disorders including gastroesophageal reflux disease (GERD).

177 cations in adults were dysphagia (70.1%) and gastroesophageal reflux disease (GERD)/heartburn (27.1%)

178 and safety in the treatment of patients with gastroesophageal reflux disease (GERD); similarly, lapar

179 We also included 10 patients with gastroesophageal reflux disease (GERD; age, 32-60 y; 7 w

180 n 2002 and 2005 were matched to persons with gastroesophageal reflux disease (GERD; n = 316) and to p

181 ether patient-identified domains (dysphagia, gastroesophageal reflux disease [GERD], nausea/vomiting,

182 For the gastric cardia, the contributions of gastroesophageal reflux disease, H. pylori infection, an

183 rm outcome of ARS in pediatric patients with gastroesophageal reflux disease have shown good to excel

184 months improved in patients with normal GE (Gastroesophageal Reflux Disease Health-Related Quality o

185 is a laryngeal symptom that can be caused by gastroesophageal reflux disease; however, treatment outc

186 atients included degenerative joint disease, gastroesophageal reflux disease, hypertension, urinary s

187 imary laparoscopic antireflux surgery due to gastroesophageal reflux disease in adults (>18 years).

188 BMI is associated with symptoms of gastroesophageal reflux disease in both normal-weight an

189 re of the height in meters - and symptoms of gastroesophageal reflux disease in persons of normal wei

190 related to the acidic environment caused by gastroesophageal reflux disease in the gastroesophageal

191 Gastroesophageal reflux disease is a common clinical pro

192 Gastroesophageal reflux disease is a highly prevalent ch

193 Gastroesophageal reflux disease is a highly prevalent di

194 Gastroesophageal reflux disease is a prevalent disorder

195 Gastroesophageal reflux disease is common in adults of a

196 integrated concept of the pathophysiology of gastroesophageal reflux disease is constructed.

197 alivary protective factors in patient s with gastroesophageal reflux disease is impaired.

198 of the lower esophagus epithelium related to gastroesophageal reflux disease, is the strongest known

199 the AGA Institute on "Endoscopic Therapy for Gastroesophageal Reflux Disease." It was approved by the

200 w endoscopic therapies have emerged to treat gastroesophageal reflux disease itself.

201 ssue injury in the esophagus associated with gastroesophageal reflux disease may result in sensitizat

202 a diligent search for an esophageal etiology-gastroesophageal reflux disease, motility abnormalities,

203 itant chemical carcinogen treatment leads to gastroesophageal reflux disease, multilayered epithelium

204 nths after fundoplication for PPI-refractory gastroesophageal reflux disease (n = 14 270 degrees LPF

205 (n = 296 cases) were matched to persons with gastroesophageal reflux disease (n = 308) without Barret

206 ad EoE (n = 17), indeterminate EoE (n = 15), gastroesophageal reflux disease (n = 7), or normal esoph

207 With improved understanding of gastroesophageal reflux disease, newer developments in d

208 on airway disease, including rhinosinusitis, gastroesophageal reflux disease, obesity and dysfunction

209 esophageal sphincter (LES) in patients with gastroesophageal reflux disease often has a low resting

210 is (EoE) was historically distinguished from gastroesophageal reflux disease on the basis of histolog

211 ceiving long-term proton pump inhibitors for gastroesophageal reflux disease or in patients with any

212 ated with EoE (or indeterminate EoE) but not gastroesophageal reflux disease or normal esophagus and

213 intravenous therapy in patients with severe gastroesophageal reflux disease or the Zollinger-Ellison

214 , including history of peptic ulcer disease, gastroesophageal reflux disease, or gastrointestinal ble

215 This article is a review of gastroesophageal reflux disease, other types of esophagi

216 Glasgow Coma Scale score <9 (p = .021), and gastroesophageal reflux disease (p = .033).

217 We randomly assigned 64 gastroesophageal reflux disease patients to radiofrequen

218 esents a new option for selected symptomatic gastroesophageal reflux disease patients who are intoler

219 Too much acid can lead to gastroesophageal reflux disease, peptic ulcer disease, a

220 5), and more had a >50% improvement in their gastroesophageal reflux disease quality of life score (n

221 This chapter reviews the biology of gastroesophageal reflux disease, relating pathophysiolog

222 Endoscopic therapies for gastroesophageal reflux disease represent a minimally in

223 ted with a relatively high rate of recurrent gastroesophageal reflux disease requiring treatment, dim

224 Nausea related to gastroesophageal reflux disease resolves or is markedly

225 premorbid prevalence of anxiety, headaches, gastroesophageal reflux disease, sleep apnea, and infect

226 ministered a modified version of a validated gastroesophageal reflux disease-specific QOL tool to pat

227 Quality of life, measured by the gastroesophageal reflux disease-specific QOL tool, and r

228 44 patients (52%) had objective findings of gastroesophageal reflux disease, such as esophagitis.

229 Symptoms improved in group A, with the Gastroesophageal Reflux Disease Symptom Assessment Scale

230 uency energy delivery significantly improved gastroesophageal reflux disease symptoms and quality of

231 racticed, its value in patients with chronic gastroesophageal reflux disease symptoms is of unproven

232 ng upper endoscopy for patients with chronic gastroesophageal reflux disease symptoms to assess for B

233 men in the United Kingdom with histories of gastroesophageal reflux disease symptoms, assuming the p

234 ost commonly occurs in patients with chronic gastroesophageal reflux disease that involves recurring

235 Triggered by gastroesophageal reflux disease, the origin of this meta

236 ic conditions (hypertension, hyperlipidemia, gastroesophageal reflux disease, thyroid disease, diabet

237 inistration recently cleared new endoluminal gastroesophageal reflux disease treatments; however, no

238 The history of gastroesophageal reflux disease was highly prevalent in

239 Gastroesophageal reflux disease was identified as an imp

240 De novo gastroesophageal reflux disease was reported in 43.8%.

241 atic treatment of nocturnal heartburn due to gastroesophageal reflux disease, was approved by the US

242 Markers of gastroesophageal reflux disease were compared between gr

243 all publications relating to both asthma and gastroesophageal reflux disease were retrieved.

244 nflammation in squamous epithelium caused by gastroesophageal reflux disease, whereas intestinal meta

245 Except for gastroesophageal reflux disease, which showed a higher r

246 Patients with gastroesophageal reflux disease who have a partial respo

247 for 5.2 million visits annually, followed by gastroesophageal reflux disease, with 4.5 million visits

248 l adenocarcinoma (BEAC) is a complication of gastroesophageal reflux disease, with no effective chemo